Completed PHASE3 INTERVENTIONAL NCT00048113

Alicaforsen (ISIS 2302) in Patients With Active Crohn's Disease

ISIS 2302-CS20, Phase 3 Double-Masked, Placebo-Controlled Study of Alicaforsen (ISIS 2302), an Antisense Inhibitor of ICAM-1, for the Treatment of Patients With Active Crohn's Disease

Sponsor: Ionis Pharmaceuticals, Inc.

Conditions Crohn's Disease

Interventions Alicaforsen

Updated 7 times since 2017 Last updated: Dec 1, 2022 Started: Jan 10, 2001 Primary completion: Apr 27, 2002 Completion: Apr 27, 2002

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00048113, this PHASE3 trial focuses on Crohn's Disease and remains completed. Sponsored by Ionis Pharmaceuticals, Inc., it has been updated 7 times since 2001, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2023 — Jul 2024 [monthly]

Completed PHASE3
Jan 2021 — Jan 2023 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Jan 2001

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Ionis Pharmaceuticals, Inc.

Data source: Ionis Pharmaceuticals, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Arvada, United States , Baltimore, United States , Buffalo, United States , Chevy Chase, United States , Chicago, United States , Cincinnati, United States , Cleveland, United States , Detroit, United States , Edmonton, Canada , Greensboro, United States and 20 more locations